ILMN Illumina, Inc.
Illumina, Inc. engages in the development and manufacture of integrated systems for the analysis of genetic variation and function. It operates through the Core Illumina and Consolidated Variable Interest Entity segments (VIE). The Core Illumina segments serve customers in the research, clinical and applied markets, and enable the adoption of genomic solutions. The Consolidated VIE segment includes activities of GRAIL and Helix. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.
Company profile
Ticker
ILMN
Exchange
CEO
Francis A. deSouza
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
Former names
Illumina Inc
SEC CIK
Corporate docs
IRS number
330804655
ILMN stock data
()
Calendar
31 Jul 19
14 Oct 19
29 Dec 19
News
Company financial data Financial data
| Quarter (USD) | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|
| Revenue | 838M | 846M | 867M | 853M | |
| Net income | 296M | 233M | 210M | 199M | |
| Diluted EPS | 1.99 | 1.57 | 1.41 | 1.33 | |
| Net profit margin | 35.32% | 27.54% | 24.22% | 23.33% | |
| Operating income | 205M | 204M | 197M | 241M | |
| Net change in cash | -202M | 2M | |||
| Cash on hand | 1.14B | 1.35B | |||
| Cost of revenue | 265M | 262M | 277M | 256M |
Financial data from Illumina earnings reports
Financial report summary
?Competition
Thermo Fisher Scientific • BGI • Ceres • Roche Holding • Solexa • Luminex • Biocept • Agilent • Third Wave • CareDxManagement Discussion
- To enhance comparability, the following table sets forth unaudited condensed consolidated statement of operations data for the specified reporting periods, stated as a percentage of total revenue.
- Our fiscal year is the 52 or 53 weeks ending the Sunday closest to December 31, with quarters of 13 or 14 weeks ending the Sunday closest to March 31, June 30, September 30, and December 31. The three and six month periods ended June 30, 2019 and July 1, 2018 were both 13 and 26 weeks, respectively.
- Service and other revenue consists primarily of sequencing and genotyping service revenue as well as instrument service contract revenue. Total revenue relates primarily to Core Illumina for all periods presented.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
arrangement, assumption, binding, Carlo, delayed, DTC, favorable, flat, focused, iii, iv, microarray, Monte, population, relieved, repaid, response, simulation, unobservable
Removed:
allocation, approximate, beginning, bona, committed, embedded, entity, event, exercisable, fide, financed, formed, group, immaterial, individual, January, laboratory, lack, marketplace, occurred, party, permitted, perpetual, policy, pursue, pursuit, put, receiving, settle, setup, subsequent, unrelated
Financial reports
10-Q
2019 Q2
Quarterly report
31 Jul 19
10-Q
2019 Q1
Quarterly report
26 Apr 19
10-K
2018 FY
Annual report
12 Feb 19
10-Q
2018 Q3
Quarterly report
23 Oct 18
10-Q
2018 Q2
Quarterly report
31 Jul 18
10-Q
2018 Q1
Quarterly report
25 Apr 18
10-K
2017 FY
Annual report
13 Feb 18
10-Q
2017 Q3
Quarterly report
25 Oct 17
10-Q
2017 Q2
Quarterly report
3 Aug 17
10-Q
2017 Q1
Quarterly report
5 May 17
Current reports
8-K
Entry into a Material Definitive Agreement
26 Sep 19
8-K
Departure of Directors or Certain Officers
29 Aug 19
8-K
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2019
29 Jul 19
8-K
Illumina Reports Preliminary Revenue for Second Quarter of Fiscal Year 2019
11 Jul 19
8-K
Other Events
18 Jun 19
8-K
Submission of Matters to a Vote of Security Holders
3 Jun 19
8-K
Illumina Reports Financial Results for First Quarter of Fiscal Year 2019
25 Apr 19
8-K
Illumina Names Susan E. Siegel to its Board of Directors
6 Feb 19
8-K
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2018
29 Jan 19
8-K
Results of Operations and Financial Condition
9 Jan 19
Registration and prospectus
S-8
Registration of securities for employees
7 Aug 15
S-8
Registration of securities for employees
2 Aug 13
S-8
Registration of securities for employees
19 Apr 13
SC TO-T/A
Third party tender offer statement (amended)
23 Apr 12
SC 14D9/A
Tender offer solicitation (amended)
18 Apr 12
SC TO-T/A
Third party tender offer statement (amended)
18 Apr 12
SC TO-T/A
Third party tender offer statement (amended)
12 Apr 12
SC TO-T/A
Third party tender offer statement (amended)
11 Apr 12
SC 14D9/A
Tender offer solicitation (amended)
10 Apr 12
SC 14D9/A
Tender offer solicitation (amended)
9 Apr 12
Proxies
DEFA14A
Additional proxy soliciting materials
24 May 19
DEFA14A
Additional proxy soliciting materials
16 Apr 19
DEF 14A
Definitive proxy
16 Apr 19
PRE 14A
Preliminary proxy
25 Mar 19
DFAN14A
Additional proxy materials by non-management
5 Nov 18
DFAN14A
Additional proxy materials by non-management
2 Nov 18
DEF 14A
Definitive proxy
6 Apr 18
DEFA14A
Additional proxy soliciting materials
6 Apr 18
DEF 14A
Definitive proxy
14 Apr 17
DEFA14A
Additional proxy soliciting materials
14 Apr 17
Other
SD
Conflict minerals disclosure
14 May 19
SD
Conflict minerals disclosure
30 May 18
CT ORDER
Confidential treatment order
9 Mar 18
SD
Conflict minerals disclosure
5 Jun 17
NO ACT
No action letter
25 Jan 17
SD
Conflict minerals disclosure
25 May 16
NO ACT
No action letter
18 Mar 16
CT ORDER
Confidential treatment order
24 Aug 15
SD
Conflict minerals disclosure
29 May 15
NO ACT
No action letter
17 Feb 15
Patents
APP
Utility
Optical Cleaning Cartridge
10 Oct 19
An optical cleaning cartridge for automated cleaning of optical components of analysis instruments is disclosed.
APP
Utility
Preserving Genomic Connectivity Information In Fragmented Genomic Dna Samples
10 Oct 19
A method of sequencing a target nucleic acid polymer by (a) modifying a target nucleic acid polymer to produce a modified nucleic acid polymer; (b) producing fragments of the modified nucleic acid polymer, wherein the fragments are attached to locations on a solid support surface (c) determining nucleotide sequences from the fragments at the locations; and (d) producing a representation of the nucleotide sequence for the target nucleic acid polymer based on the nucleotide sequences from the fragments and the relative distances between the locations on the solid support surface.
GRANT
Utility
Integrated consumer genomic services
8 Oct 19
The present invention provides a novel approach for consumer-driven interaction with sequencing data or genomic information.
APP
Utility
Cartridge Assembly
3 Oct 19
A cartridge assembly comprises a housing having an illumination chamber and a well plate.
APP
Utility
Illumination for Fluorescence Imaging Using Objective Lens
3 Oct 19
A system includes: an objective lens; a first light source to feed first illuminating light through the objective lens and into a flowcell (e.g., with a relatively thin film waveguide) to be installed in the system, the first illuminating light to be fed using a first grating on the flowcell; and a first image sensor to capture imaging light using the objective lens, wherein the first grating is positioned outside a field of view of the first image sensor.